Back to Search Start Over

Defining Utility Values for Chorea Health States in Patients with Huntington's Disease.

Authors :
Claassen DO
Ayyagari R
Goldschmidt D
Zhou M
Leo S
Ribalov R
Source :
Advances in therapy [Adv Ther] 2022 Apr; Vol. 39 (4), pp. 1784-1793. Date of Electronic Publication: 2022 Feb 23.
Publication Year :
2022

Abstract

Introduction: Chorea is characterized by sudden, involuntary movements that interfere with quality of life (QOL). Utility values measure preferences for different health states and reflect societal perceived disease severity. To date, no studies have reported utility values specifically for Huntington's disease (HD) chorea. We estimated impact on QOL of HD chorea severity using utility values from the general population.<br />Methods: Participants were enrolled using computer-assisted telephone interviews. Participants read vignettes describing four health states for varying levels of chorea severity, with the same underlying HD severity. Time trade-off (TTO) methods were used to estimate utility values, which range from -1 (worse than death) to +1 (perfect health) and represent the number of years in an imperfect health state an individual is willing to give up to live in full health. TTO utilities were augmented with visual analog scale (VAS) participant responses. The primary outcome was HD chorea utility estimated by TTO.<br />Results: Mean ± SD TTO-derived utility values were 0.07 ± 0.52, 0.26 ± 0.50, 0.48 ± 0.47, and 0.64 ± 0.41 for severe, moderate/severe, moderate/mild, and mild chorea severity, respectively. Differences between each health state and its adjacent less severe health state were statistically significant (all P < 0.0001). Respondents were willing to give up 3.6, 5.2, 7.4, and 9.3 years during a 10-year life span to avoid living with mild, mild/moderate, moderate/severe, and severe chorea, respectively. VAS and TTO results were consistent.<br />Conclusions: Significant decreases in utility values were seen as HD chorea severity increased. These data can be leveraged for cost-effectiveness modeling to better understand the value of treatments for chorea.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
1865-8652
Volume :
39
Issue :
4
Database :
MEDLINE
Journal :
Advances in therapy
Publication Type :
Academic Journal
Accession number :
35195860
Full Text :
https://doi.org/10.1007/s12325-022-02046-z